{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:34:53Z","timestamp":1789425293440,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT06239441"],"award-info":[{"award-number":["NCT06239441"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.03.025","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:13:36Z","timestamp":1743041616000},"page":"1768-1775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Response to IL-5\/IL-5R Antagonists and Remission Rate in Patients With Severe Asthma Who Would Have Been Excluded From the Pivotal Clinical Trials"],"prefix":"10.1016","volume":"13","author":[{"given":"Claudia","family":"Blouin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-9628","authenticated-orcid":false,"given":"Catherine","family":"Lemiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.03.025_bib2","first-page":"199","article-title":"Recognition and management of severe asthma: a Canadian Thoracic Society position statement","volume":"1","author":"FitzGerald","year":"2017","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.03.025_bib4","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2025.03.025_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib9","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.03.025_bib10","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.03.025_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.03.025_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.03.025_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.03.025_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"Nagase","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.03.025_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.03.025_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: a call for a globally standardised definition","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.03.025_bib19","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.03.025_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.03.025_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.03.025_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"super-responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.03.025_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.03.025_bib26","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.025_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"issue":"suppl 67","key":"10.1016\/j.jaip.2025.03.025_bib28","article-title":"Durability of benralizumab-induced remission in severe asthma: an analysis of the BORA study","volume":"62","author":"Lommatzsch","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.03.025_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.03.025_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.03.025_bib31","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.3390\/ijms24119563","article-title":"Switching biological therapies in severe asthma","volume":"24","author":"Scioscia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.03.025_bib32","doi-asserted-by":"crossref","first-page":"A75","DOI":"10.1016\/j.chest.2023.07.102","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"164","author":"Bagnasco","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.03.025_bib33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib34","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.03.025_bib35","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/thorax-2022-219781","article-title":"Super-responders to anti-IL-5\/anti-IL-5R are characterised by high sputum eosinophil counts at baseline","volume":"78","author":"Gerday","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.03.025_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.03.025_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.03.025_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00586-2022","article-title":"Characteristics of severe asthma patients on biologics: a real-life European registry study","volume":"9","author":"Principe","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.03.025_bib39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:53:03Z","timestamp":1778853183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825002764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825002764"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.03.025","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to IL-5\/IL-5R Antagonists and Remission Rate in Patients With Severe Asthma Who Would Have Been Excluded From the Pivotal Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}